繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

PolyPid Files for Potential Sale of 3.9 Million Shares

2024-08-31 05:03

05:03 PM EDT, 08/30/2024 (MT Newswires) -- PolyPid (PYPD) filed a registration statement Friday with the US Securities and Exchange Commission for the potential sale of up to 3.9 million ordinary shares.

The filing covers 2 million ordinary shares held by the selling shareholders, 1.7 million shares issuable upon the exercise of warrants, and 229,231 shares issuable upon the exercise of pre-funded warrants, the company said.

PolyPid said it will not receive any proceeds from the sale of shares by the selling shareholders.

The company, however, will obtain proceeds from the exercise of warrants and pre-funded warrants, which will be used for the ongoing Shield II phase 3 trial for the prevention of infections in patients undergoing abdominal colorectal surgery, as well as for working capital and general corporate purposes, PolyPid said.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。